|
Market Closed -
Nasdaq
01:30:00 30/05/2025 am IST
|
5-day change | 1st Jan Change | ||
| 4.260 USD | +0.71% |
|
-.--% | - |
Company Valuation: Checkpoint Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 88.79 | 179.9 | 260.5 | 52.39 | 53.87 | 156.3 |
| Change | - | 102.61% | 44.83% | -79.89% | 2.84% | 190.05% |
| Enterprise Value (EV) 1 | 62.71 | 139.1 | 205.8 | 40.32 | 48.95 | 149.7 |
| Change | - | 121.85% | 47.93% | -80.41% | 21.4% | 205.76% |
| P/E | -2.46x | -6.41x | -4.64x | -0.84x | -1.23x | -2.26x |
| PBR | 4.93x | 5.2x | 8.84x | -2.7x | -4.87x | -13.8x |
| PEG | - | 0.2x | -0.1x | 0.09x | 0x | 0.1x |
| Capitalization / Revenue | 52x | 168x | 972x | 273x | 523x | 3,811x |
| EV / Revenue | 36.7x | 130x | 768x | 210x | 475x | 3,650x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -2.52x | -6x | -3.63x | -0.69x | -0.94x | -2.66x |
| EV / FCF | -4.08x | -10.3x | -16.2x | -1.49x | -1.13x | -8.05x |
| FCF Yield | -24.5% | -9.75% | -6.18% | -66.9% | -88.4% | -12.4% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -7 | -4.134 | -6.701 | -6.088 | -1.869 | -1.418 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 1.708 | 1.069 | 0.268 | 0.192 | 0.103 | 0.041 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -24.85 | -23.2 | -56.72 | -58.33 | -52.15 | -56.17 |
| Net income 1 | -24.71 | -23.08 | -56.67 | -62.62 | -51.85 | -56.24 |
| Net Debt 1 | -26.08 | -40.77 | -54.74 | -12.07 | -4.928 | -6.604 |
| Reference price 2 | 17.200 | 26.500 | 31.100 | 5.110 | 2.290 | 3.200 |
| Nbr of stocks (in thousands) | 5,162 | 6,788 | 8,377 | 10,252 | 23,526 | 48,833 |
| Announcement Date | 11/03/20 | 12/03/21 | 28/03/22 | 31/03/23 | 22/03/24 | 28/03/25 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 36Cr | |
| 21.73x | 7.76x | 15.59x | 1.37% | 7.47TCr | |
| 30.5x | 8.78x | 27.34x | 0.04% | 5.87TCr | |
| 33.66x | 6.05x | 18.11x | 0.96% | 4.84TCr | |
| -20.81x | 215.3x | -22.29x | -.--% | 4.31TCr | |
| 33.24x | 3.23x | 13.97x | -.--% | 4.25TCr | |
| 48.26x | 5.5x | 30.21x | -.--% | 4.14TCr | |
| 27.77x | 7.89x | 20.51x | 0.41% | 3.13TCr | |
| -14.93x | 5.54x | -6.96x | -.--% | 2.39TCr | |
| -61.76x | 11.97x | -60.92x | -.--% | 2.22TCr | |
| Average | 10.85x | 30.22x | 3.95x | 0.31% | 3.86TCr | |
| Weighted average by Cap. | 17.34x | 30.22x | 9.46x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CKPT Stock
- Valuation Checkpoint Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
